nodes	percent_of_prediction	percent_of_DWPC	metapath
Bortezomib—Nateglinide—Lisinopril—systemic scleroderma	0.24	0.513	CrCrCtD
Bortezomib—Aspartame—Lisinopril—systemic scleroderma	0.228	0.487	CrCrCtD
Bortezomib—CYP2C8—Mometasone—systemic scleroderma	0.0495	0.267	CbGbCtD
Bortezomib—CYP1A2—Pentoxifylline—systemic scleroderma	0.0259	0.139	CbGbCtD
Bortezomib—CYP1A2—Leflunomide—systemic scleroderma	0.0247	0.133	CbGbCtD
Bortezomib—CYP2C9—Leflunomide—systemic scleroderma	0.0223	0.12	CbGbCtD
Bortezomib—CYP2C8—Mycophenolate mofetil—systemic scleroderma	0.0197	0.106	CbGbCtD
Bortezomib—CYP2D6—Captopril—systemic scleroderma	0.016	0.086	CbGbCtD
Bortezomib—CYP2C19—Prednisone—systemic scleroderma	0.0132	0.0712	CbGbCtD
Bortezomib—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00799	0.0431	CbGbCtD
Bortezomib—CYP2C9—cardial valve—systemic scleroderma	0.00664	0.106	CbGeAlD
Bortezomib—CYP3A4—Prednisone—systemic scleroderma	0.00639	0.0344	CbGbCtD
Bortezomib—CTSG—connective tissue—systemic scleroderma	0.00263	0.042	CbGeAlD
Bortezomib—PSMA1—connective tissue—systemic scleroderma	0.00252	0.0404	CbGeAlD
Bortezomib—CTSG—skin of body—systemic scleroderma	0.00237	0.0379	CbGeAlD
Bortezomib—PSMA1—skin of body—systemic scleroderma	0.00228	0.0364	CbGeAlD
Bortezomib—PSMD1—smooth muscle tissue—systemic scleroderma	0.00194	0.031	CbGeAlD
Bortezomib—PSMA1—digestive system—systemic scleroderma	0.00182	0.0291	CbGeAlD
Bortezomib—CTSG—tendon—systemic scleroderma	0.00181	0.0289	CbGeAlD
Bortezomib—PSMD2—smooth muscle tissue—systemic scleroderma	0.00172	0.0274	CbGeAlD
Bortezomib—PSMD2—skin of body—systemic scleroderma	0.00169	0.0271	CbGeAlD
Bortezomib—CTSG—lung—systemic scleroderma	0.00159	0.0254	CbGeAlD
Bortezomib—PSMA1—lung—systemic scleroderma	0.00152	0.0243	CbGeAlD
Bortezomib—PSMB5—smooth muscle tissue—systemic scleroderma	0.00151	0.0241	CbGeAlD
Bortezomib—PSMD1—tendon—systemic scleroderma	0.00146	0.0233	CbGeAlD
Bortezomib—PSMB2—connective tissue—systemic scleroderma	0.00141	0.0225	CbGeAlD
Bortezomib—PSMD2—digestive system—systemic scleroderma	0.00136	0.0217	CbGeAlD
Bortezomib—PSMB1—smooth muscle tissue—systemic scleroderma	0.00132	0.0211	CbGeAlD
Bortezomib—PSMB1—skin of body—systemic scleroderma	0.0013	0.0208	CbGeAlD
Bortezomib—PSMD2—tendon—systemic scleroderma	0.00129	0.0206	CbGeAlD
Bortezomib—PSMB2—smooth muscle tissue—systemic scleroderma	0.00129	0.0206	CbGeAlD
Bortezomib—PSMB8—tendon—systemic scleroderma	0.00128	0.0205	CbGeAlD
Bortezomib—PSMD1—lung—systemic scleroderma	0.00128	0.0204	CbGeAlD
Bortezomib—PSMB2—skin of body—systemic scleroderma	0.00127	0.0203	CbGeAlD
Bortezomib—PSMB5—tendon—systemic scleroderma	0.00113	0.0181	CbGeAlD
Bortezomib—PSMD2—lung—systemic scleroderma	0.00113	0.0181	CbGeAlD
Bortezomib—PSMB8—lung—systemic scleroderma	0.00113	0.018	CbGeAlD
Bortezomib—PSMB1—digestive system—systemic scleroderma	0.00104	0.0166	CbGeAlD
Bortezomib—PSMB2—digestive system—systemic scleroderma	0.00101	0.0162	CbGeAlD
Bortezomib—PSMB5—lung—systemic scleroderma	0.000994	0.0159	CbGeAlD
Bortezomib—PSMB1—tendon—systemic scleroderma	0.00099	0.0158	CbGeAlD
Bortezomib—PSMB2—tendon—systemic scleroderma	0.000966	0.0154	CbGeAlD
Bortezomib—PTGS1—artery—systemic scleroderma	0.000909	0.0145	CbGeAlD
Bortezomib—SLC31A1—digestive system—systemic scleroderma	0.000879	0.0141	CbGeAlD
Bortezomib—PSMB1—lung—systemic scleroderma	0.000869	0.0139	CbGeAlD
Bortezomib—PSMB2—lung—systemic scleroderma	0.000848	0.0136	CbGeAlD
Bortezomib—SLC31A1—tendon—systemic scleroderma	0.000836	0.0134	CbGeAlD
Bortezomib—PTGS1—endothelium—systemic scleroderma	0.000768	0.0123	CbGeAlD
Bortezomib—SLC31A1—lung—systemic scleroderma	0.000734	0.0117	CbGeAlD
Bortezomib—PTGS1—blood vessel—systemic scleroderma	0.000708	0.0113	CbGeAlD
Bortezomib—PSMD2—Fluticasone Propionate—Mometasone—systemic scleroderma	0.000554	0.184	CbGdCrCtD
Bortezomib—PSMB8—Fluorometholone—Mometasone—systemic scleroderma	0.000399	0.132	CbGdCrCtD
Bortezomib—CYP1A1—skin of body—systemic scleroderma	0.000373	0.00597	CbGeAlD
Bortezomib—CYP2C19—digestive system—systemic scleroderma	0.000371	0.00592	CbGeAlD
Bortezomib—PTGS1—connective tissue—systemic scleroderma	0.000363	0.00581	CbGeAlD
Bortezomib—PTGS1—smooth muscle tissue—systemic scleroderma	0.000332	0.00531	CbGeAlD
Bortezomib—PTGS1—skin of body—systemic scleroderma	0.000328	0.00524	CbGeAlD
Bortezomib—PSMB8—Diflorasone—Mometasone—systemic scleroderma	0.000304	0.101	CbGdCrCtD
Bortezomib—CYP1A2—digestive system—systemic scleroderma	0.000303	0.00484	CbGeAlD
Bortezomib—CYP1A1—digestive system—systemic scleroderma	0.000299	0.00477	CbGeAlD
Bortezomib—CYP2C9—digestive system—systemic scleroderma	0.000287	0.00459	CbGeAlD
Bortezomib—PSMD2—Dexamethasone—Mometasone—systemic scleroderma	0.000281	0.0933	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Mometasone—systemic scleroderma	0.000281	0.0933	CbGdCrCtD
Bortezomib—PTGS1—digestive system—systemic scleroderma	0.000262	0.00419	CbGeAlD
Bortezomib—CYP1A2—lung—systemic scleroderma	0.000253	0.00404	CbGeAlD
Bortezomib—PTGS1—tendon—systemic scleroderma	0.00025	0.00399	CbGeAlD
Bortezomib—CYP1A1—lung—systemic scleroderma	0.000249	0.00399	CbGeAlD
Bortezomib—CYP3A4—digestive system—systemic scleroderma	0.000219	0.0035	CbGeAlD
Bortezomib—PTGS1—lung—systemic scleroderma	0.000219	0.0035	CbGeAlD
Bortezomib—PSMB8—Fluorometholone—Prednisone—systemic scleroderma	0.000217	0.0722	CbGdCrCtD
Bortezomib—CYP2D6—digestive system—systemic scleroderma	0.000216	0.00345	CbGeAlD
Bortezomib—PSMB8—Diflorasone—Prednisone—systemic scleroderma	0.000166	0.055	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Mometasone—systemic scleroderma	0.000163	0.0541	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Mometasone—systemic scleroderma	0.000163	0.0541	CbGdCrCtD
Bortezomib—PSMD2—Betamethasone—Prednisone—systemic scleroderma	0.000153	0.0508	CbGdCrCtD
Bortezomib—PSMD2—Dexamethasone—Prednisone—systemic scleroderma	0.000153	0.0508	CbGdCrCtD
Bortezomib—PSMB8—Betamethasone—Prednisone—systemic scleroderma	8.88e-05	0.0295	CbGdCrCtD
Bortezomib—PSMB8—Dexamethasone—Prednisone—systemic scleroderma	8.88e-05	0.0295	CbGdCrCtD
Bortezomib—PSMA1—Signaling Pathways—SMAD7—systemic scleroderma	6.12e-05	0.000707	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CSK—systemic scleroderma	6.1e-05	0.000704	CbGpPWpGaD
Bortezomib—PSMA1—Adaptive Immune System—CD40LG—systemic scleroderma	6.09e-05	0.000703	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—SMAD7—systemic scleroderma	6.09e-05	0.000703	CbGpPWpGaD
Bortezomib—PSMD1—Adaptive Immune System—CD40LG—systemic scleroderma	6.06e-05	0.0007	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—SMAD7—systemic scleroderma	6.06e-05	0.0007	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFBI—systemic scleroderma	6.06e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFBI—systemic scleroderma	6.06e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFBI—systemic scleroderma	6.06e-05	0.000699	CbGpPWpGaD
Bortezomib—PSMD2—Adaptive Immune System—CD40LG—systemic scleroderma	6.04e-05	0.000697	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFBI—systemic scleroderma	5.97e-05	0.000689	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CTLA4—systemic scleroderma	5.94e-05	0.000685	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CTLA4—systemic scleroderma	5.94e-05	0.000685	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—CTLA4—systemic scleroderma	5.94e-05	0.000685	CbGpPWpGaD
Bortezomib—PTGS1—Selenium Micronutrient Network—IL1B—systemic scleroderma	5.94e-05	0.000685	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—TNFAIP3—systemic scleroderma	5.87e-05	0.000678	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CTLA4—systemic scleroderma	5.85e-05	0.000676	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—TNFAIP3—systemic scleroderma	5.84e-05	0.000675	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—TNFAIP3—systemic scleroderma	5.82e-05	0.000671	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—BLK—systemic scleroderma	5.8e-05	0.00067	CbGpPWpGaD
Bortezomib—PSMA1—Disease—CD247—systemic scleroderma	5.79e-05	0.000668	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—BLK—systemic scleroderma	5.77e-05	0.000667	CbGpPWpGaD
Bortezomib—PSMD1—Disease—CD247—systemic scleroderma	5.76e-05	0.000665	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—BLK—systemic scleroderma	5.75e-05	0.000663	CbGpPWpGaD
Bortezomib—PSMD2—Disease—CD247—systemic scleroderma	5.73e-05	0.000662	CbGpPWpGaD
Bortezomib—CYP1A1—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	5.46e-05	0.00063	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—HSPG2—systemic scleroderma	5.34e-05	0.000616	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—HSPG2—systemic scleroderma	5.31e-05	0.000613	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—HSPG2—systemic scleroderma	5.29e-05	0.000611	CbGpPWpGaD
Bortezomib—PSMA1—Gene Expression—CTGF—systemic scleroderma	5.2e-05	0.000601	CbGpPWpGaD
Bortezomib—PSMD1—Gene Expression—CTGF—systemic scleroderma	5.18e-05	0.000598	CbGpPWpGaD
Bortezomib—PSMD2—Gene Expression—CTGF—systemic scleroderma	5.15e-05	0.000595	CbGpPWpGaD
Bortezomib—Acute coronary syndrome—Prednisone—systemic scleroderma	5.07e-05	0.00026	CcSEcCtD
Bortezomib—PSMB2—Immune System—CSK—systemic scleroderma	5.05e-05	0.000583	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CSK—systemic scleroderma	5.05e-05	0.000583	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CSK—systemic scleroderma	5.05e-05	0.000583	CbGpPWpGaD
Bortezomib—Feeling abnormal—Mycophenolic acid—systemic scleroderma	5.05e-05	0.000259	CcSEcCtD
Bortezomib—Myalgia—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000259	CcSEcCtD
Bortezomib—Chest pain—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000259	CcSEcCtD
Bortezomib—Arthralgia—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.000259	CcSEcCtD
Bortezomib—Myocardial infarction—Prednisone—systemic scleroderma	5.04e-05	0.000258	CcSEcCtD
Bortezomib—Neuropathy peripheral—Prednisone—systemic scleroderma	5.04e-05	0.000258	CcSEcCtD
Bortezomib—Breast disorder—Methotrexate—systemic scleroderma	5.04e-05	0.000258	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	5.03e-05	0.000258	CcSEcCtD
Bortezomib—Anxiety—Mycophenolate mofetil—systemic scleroderma	5.03e-05	0.000258	CcSEcCtD
Bortezomib—Toxic epidermal necrolysis—Methotrexate—systemic scleroderma	5.02e-05	0.000257	CcSEcCtD
Bortezomib—Hypersensitivity—Azathioprine—systemic scleroderma	5.01e-05	0.000257	CcSEcCtD
Bortezomib—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	5.01e-05	0.000257	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.01e-05	0.000257	CcSEcCtD
Bortezomib—Insomnia—Lisinopril—systemic scleroderma	5e-05	0.000256	CcSEcCtD
Bortezomib—Discomfort—Mycophenolate mofetil—systemic scleroderma	4.99e-05	0.000256	CcSEcCtD
Bortezomib—PSMB8—Immune System—CSK—systemic scleroderma	4.98e-05	0.000575	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IRF5—systemic scleroderma	4.97e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IRF5—systemic scleroderma	4.97e-05	0.000574	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IRF5—systemic scleroderma	4.97e-05	0.000574	CbGpPWpGaD
Bortezomib—Paraesthesia—Lisinopril—systemic scleroderma	4.96e-05	0.000254	CcSEcCtD
Bortezomib—Vomiting—Captopril—systemic scleroderma	4.96e-05	0.000254	CcSEcCtD
Bortezomib—Dyspnoea—Lisinopril—systemic scleroderma	4.92e-05	0.000252	CcSEcCtD
Bortezomib—Rash—Captopril—systemic scleroderma	4.92e-05	0.000252	CcSEcCtD
Bortezomib—Dermatitis—Captopril—systemic scleroderma	4.91e-05	0.000252	CcSEcCtD
Bortezomib—PSMB8—Immune System—IRF5—systemic scleroderma	4.9e-05	0.000566	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.89e-05	0.000564	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.89e-05	0.000564	CbGpPWpGaD
Bortezomib—PSMB5—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.89e-05	0.000564	CbGpPWpGaD
Bortezomib—Headache—Captopril—systemic scleroderma	4.89e-05	0.00025	CcSEcCtD
Bortezomib—Confusional state—Mycophenolate mofetil—systemic scleroderma	4.88e-05	0.00025	CcSEcCtD
Bortezomib—Dyspepsia—Lisinopril—systemic scleroderma	4.86e-05	0.000249	CcSEcCtD
Bortezomib—Abdominal pain—Mycophenolic acid—systemic scleroderma	4.85e-05	0.000249	CcSEcCtD
Bortezomib—Body temperature increased—Mycophenolic acid—systemic scleroderma	4.85e-05	0.000249	CcSEcCtD
Bortezomib—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	4.84e-05	0.000248	CcSEcCtD
Bortezomib—Oedema—Mycophenolate mofetil—systemic scleroderma	4.84e-05	0.000248	CcSEcCtD
Bortezomib—PSMB2—Disease—HSPG2—systemic scleroderma	4.83e-05	0.000558	CbGpPWpGaD
Bortezomib—PSMB1—Disease—HSPG2—systemic scleroderma	4.83e-05	0.000558	CbGpPWpGaD
Bortezomib—PSMB5—Disease—HSPG2—systemic scleroderma	4.83e-05	0.000558	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—HLA-DQB1—systemic scleroderma	4.82e-05	0.000557	CbGpPWpGaD
Bortezomib—Infection—Mycophenolate mofetil—systemic scleroderma	4.81e-05	0.000246	CcSEcCtD
Bortezomib—Decreased appetite—Lisinopril—systemic scleroderma	4.8e-05	0.000246	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Lisinopril—systemic scleroderma	4.77e-05	0.000244	CcSEcCtD
Bortezomib—PSMB8—Disease—HSPG2—systemic scleroderma	4.76e-05	0.00055	CbGpPWpGaD
Bortezomib—Fatigue—Lisinopril—systemic scleroderma	4.76e-05	0.000244	CcSEcCtD
Bortezomib—Shock—Mycophenolate mofetil—systemic scleroderma	4.76e-05	0.000244	CcSEcCtD
Bortezomib—PSMB2—Immune System—IRF8—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IRF8—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IRF8—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CTLA4—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CD247—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—ITGAM—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—ITGAM—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD247—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—ITGAM—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD247—systemic scleroderma	4.75e-05	0.000549	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	4.75e-05	0.000548	CbGpPWpGaD
Bortezomib—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	4.75e-05	0.000243	CcSEcCtD
Bortezomib—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	4.74e-05	0.000243	CcSEcCtD
Bortezomib—Hypersensitivity—Leflunomide—systemic scleroderma	4.74e-05	0.000243	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—RHOB—systemic scleroderma	4.73e-05	0.000547	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CTLA4—systemic scleroderma	4.73e-05	0.000546	CbGpPWpGaD
Bortezomib—Pancreatitis—Methotrexate—systemic scleroderma	4.73e-05	0.000242	CcSEcCtD
Bortezomib—Pain—Lisinopril—systemic scleroderma	4.72e-05	0.000242	CcSEcCtD
Bortezomib—Constipation—Lisinopril—systemic scleroderma	4.72e-05	0.000242	CcSEcCtD
Bortezomib—Tachycardia—Mycophenolate mofetil—systemic scleroderma	4.72e-05	0.000242	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—RHOB—systemic scleroderma	4.71e-05	0.000544	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—CTLA4—systemic scleroderma	4.71e-05	0.000543	CbGpPWpGaD
Bortezomib—Skin disorder—Mycophenolate mofetil—systemic scleroderma	4.7e-05	0.000241	CcSEcCtD
Bortezomib—Bradycardia—Prednisone—systemic scleroderma	4.7e-05	0.000241	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—RHOB—systemic scleroderma	4.69e-05	0.000541	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IRF8—systemic scleroderma	4.69e-05	0.000541	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—ITGAM—systemic scleroderma	4.69e-05	0.000541	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—CD247—systemic scleroderma	4.69e-05	0.000541	CbGpPWpGaD
Bortezomib—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.68e-05	0.00024	CcSEcCtD
Bortezomib—PSMB1—Disease—CSK—systemic scleroderma	4.67e-05	0.000539	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CSK—systemic scleroderma	4.67e-05	0.000539	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CSK—systemic scleroderma	4.67e-05	0.000539	CbGpPWpGaD
Bortezomib—Diarrhoea—Azathioprine—systemic scleroderma	4.66e-05	0.000239	CcSEcCtD
Bortezomib—Haemoglobin—Prednisone—systemic scleroderma	4.64e-05	0.000238	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—SMAD7—systemic scleroderma	4.64e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—SMAD7—systemic scleroderma	4.64e-05	0.000535	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—SMAD7—systemic scleroderma	4.64e-05	0.000535	CbGpPWpGaD
Bortezomib—Nausea—Captopril—systemic scleroderma	4.63e-05	0.000237	CcSEcCtD
Bortezomib—Abdominal discomfort—Methotrexate—systemic scleroderma	4.62e-05	0.000237	CcSEcCtD
Bortezomib—PSMB5—Adaptive Immune System—CD40LG—systemic scleroderma	4.62e-05	0.000533	CbGpPWpGaD
Bortezomib—PSMB1—Adaptive Immune System—CD40LG—systemic scleroderma	4.62e-05	0.000533	CbGpPWpGaD
Bortezomib—PSMB2—Adaptive Immune System—CD40LG—systemic scleroderma	4.62e-05	0.000533	CbGpPWpGaD
Bortezomib—Haemorrhage—Prednisone—systemic scleroderma	4.62e-05	0.000237	CcSEcCtD
Bortezomib—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.61e-05	0.000236	CcSEcCtD
Bortezomib—Asthenia—Leflunomide—systemic scleroderma	4.61e-05	0.000236	CcSEcCtD
Bortezomib—PSMB8—Disease—CSK—systemic scleroderma	4.6e-05	0.000531	CbGpPWpGaD
Bortezomib—Hallucination—Prednisone—systemic scleroderma	4.59e-05	0.000236	CcSEcCtD
Bortezomib—Pancytopenia—Methotrexate—systemic scleroderma	4.58e-05	0.000235	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—SMAD7—systemic scleroderma	4.57e-05	0.000528	CbGpPWpGaD
Bortezomib—PSMB8—Adaptive Immune System—CD40LG—systemic scleroderma	4.55e-05	0.000526	CbGpPWpGaD
Bortezomib—Feeling abnormal—Lisinopril—systemic scleroderma	4.55e-05	0.000233	CcSEcCtD
Bortezomib—Pruritus—Leflunomide—systemic scleroderma	4.55e-05	0.000233	CcSEcCtD
Bortezomib—Connective tissue disorder—Prednisone—systemic scleroderma	4.54e-05	0.000233	CcSEcCtD
Bortezomib—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.52e-05	0.000232	CcSEcCtD
Bortezomib—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.52e-05	0.000232	CcSEcCtD
Bortezomib—Neutropenia—Methotrexate—systemic scleroderma	4.51e-05	0.000231	CcSEcCtD
Bortezomib—Dizziness—Azathioprine—systemic scleroderma	4.5e-05	0.000231	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL1B—systemic scleroderma	4.48e-05	0.000517	CbGpPWpGaD
Bortezomib—Upper respiratory tract infection—Methotrexate—systemic scleroderma	4.48e-05	0.00023	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—HSPG2—systemic scleroderma	4.46e-05	0.000515	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—TNFAIP3—systemic scleroderma	4.45e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—TNFAIP3—systemic scleroderma	4.45e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—TNFAIP3—systemic scleroderma	4.45e-05	0.000514	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—HSPG2—systemic scleroderma	4.44e-05	0.000513	CbGpPWpGaD
Bortezomib—Erectile dysfunction—Methotrexate—systemic scleroderma	4.44e-05	0.000228	CcSEcCtD
Bortezomib—PSMB8—Cytokine Signaling in Immune system—IL1B—systemic scleroderma	4.43e-05	0.000512	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—HSPG2—systemic scleroderma	4.42e-05	0.000511	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.41e-05	0.000226	CcSEcCtD
Bortezomib—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.4e-05	0.000226	CcSEcCtD
Bortezomib—Asthenia—Mycophenolic acid—systemic scleroderma	4.4e-05	0.000226	CcSEcCtD
Bortezomib—Diarrhoea—Leflunomide—systemic scleroderma	4.4e-05	0.000225	CcSEcCtD
Bortezomib—PSMB2—Immune System—BLK—systemic scleroderma	4.4e-05	0.000508	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—BLK—systemic scleroderma	4.4e-05	0.000508	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—BLK—systemic scleroderma	4.4e-05	0.000508	CbGpPWpGaD
Bortezomib—Urticaria—Lisinopril—systemic scleroderma	4.39e-05	0.000225	CcSEcCtD
Bortezomib—PSMB1—Disease—CD247—systemic scleroderma	4.39e-05	0.000507	CbGpPWpGaD
Bortezomib—PSMB2—Disease—CD247—systemic scleroderma	4.39e-05	0.000507	CbGpPWpGaD
Bortezomib—PSMB5—Disease—CD247—systemic scleroderma	4.39e-05	0.000507	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—TNFAIP3—systemic scleroderma	4.39e-05	0.000506	CbGpPWpGaD
Bortezomib—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.38e-05	0.000224	CcSEcCtD
Bortezomib—Abdominal pain—Lisinopril—systemic scleroderma	4.37e-05	0.000224	CcSEcCtD
Bortezomib—Body temperature increased—Lisinopril—systemic scleroderma	4.37e-05	0.000224	CcSEcCtD
Bortezomib—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.35e-05	0.000223	CcSEcCtD
Bortezomib—Pruritus—Mycophenolic acid—systemic scleroderma	4.34e-05	0.000222	CcSEcCtD
Bortezomib—PSMB8—Immune System—BLK—systemic scleroderma	4.33e-05	0.0005	CbGpPWpGaD
Bortezomib—Vomiting—Azathioprine—systemic scleroderma	4.33e-05	0.000222	CcSEcCtD
Bortezomib—PSMB8—Disease—CD247—systemic scleroderma	4.33e-05	0.000499	CbGpPWpGaD
Bortezomib—Pneumonia—Methotrexate—systemic scleroderma	4.32e-05	0.000222	CcSEcCtD
Bortezomib—Eye disorder—Prednisone—systemic scleroderma	4.31e-05	0.000221	CcSEcCtD
Bortezomib—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.31e-05	0.000221	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CSK—systemic scleroderma	4.31e-05	0.000498	CbGpPWpGaD
Bortezomib—Infestation NOS—Methotrexate—systemic scleroderma	4.3e-05	0.00022	CcSEcCtD
Bortezomib—Infestation—Methotrexate—systemic scleroderma	4.3e-05	0.00022	CcSEcCtD
Bortezomib—Rash—Azathioprine—systemic scleroderma	4.29e-05	0.00022	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—CSK—systemic scleroderma	4.29e-05	0.000495	CbGpPWpGaD
Bortezomib—Dermatitis—Azathioprine—systemic scleroderma	4.29e-05	0.00022	CcSEcCtD
Bortezomib—Flushing—Prednisone—systemic scleroderma	4.28e-05	0.00022	CcSEcCtD
Bortezomib—PSMD2—Signaling Pathways—CSK—systemic scleroderma	4.27e-05	0.000493	CbGpPWpGaD
Bortezomib—Headache—Azathioprine—systemic scleroderma	4.26e-05	0.000219	CcSEcCtD
Bortezomib—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	4.26e-05	0.000218	CcSEcCtD
Bortezomib—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.26e-05	0.000218	CcSEcCtD
Bortezomib—Dizziness—Leflunomide—systemic scleroderma	4.25e-05	0.000218	CcSEcCtD
Bortezomib—Renal failure—Methotrexate—systemic scleroderma	4.23e-05	0.000217	CcSEcCtD
Bortezomib—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.21e-05	0.000216	CcSEcCtD
Bortezomib—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.2e-05	0.000215	CcSEcCtD
Bortezomib—Stomatitis—Methotrexate—systemic scleroderma	4.19e-05	0.000215	CcSEcCtD
Bortezomib—Angiopathy—Prednisone—systemic scleroderma	4.19e-05	0.000215	CcSEcCtD
Bortezomib—Conjunctivitis—Methotrexate—systemic scleroderma	4.18e-05	0.000214	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.18e-05	0.000214	CcSEcCtD
Bortezomib—Immune system disorder—Prednisone—systemic scleroderma	4.17e-05	0.000214	CcSEcCtD
Bortezomib—Pain—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000212	CcSEcCtD
Bortezomib—Constipation—Mycophenolate mofetil—systemic scleroderma	4.14e-05	0.000212	CcSEcCtD
Bortezomib—Arrhythmia—Prednisone—systemic scleroderma	4.12e-05	0.000211	CcSEcCtD
Bortezomib—Haematuria—Methotrexate—systemic scleroderma	4.1e-05	0.00021	CcSEcCtD
Bortezomib—Vomiting—Leflunomide—systemic scleroderma	4.09e-05	0.00021	CcSEcCtD
Bortezomib—Hypersensitivity—Lisinopril—systemic scleroderma	4.07e-05	0.000209	CcSEcCtD
Bortezomib—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.07e-05	0.000208	CcSEcCtD
Bortezomib—Dizziness—Mycophenolic acid—systemic scleroderma	4.05e-05	0.000208	CcSEcCtD
Bortezomib—Epistaxis—Methotrexate—systemic scleroderma	4.05e-05	0.000208	CcSEcCtD
Bortezomib—Rash—Leflunomide—systemic scleroderma	4.05e-05	0.000208	CcSEcCtD
Bortezomib—Dermatitis—Leflunomide—systemic scleroderma	4.05e-05	0.000208	CcSEcCtD
Bortezomib—PSMB1—Metabolism—HSPG2—systemic scleroderma	4.05e-05	0.000467	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—HSPG2—systemic scleroderma	4.05e-05	0.000467	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—CTGF—systemic scleroderma	4.05e-05	0.000467	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—HSPG2—systemic scleroderma	4.05e-05	0.000467	CbGpPWpGaD
Bortezomib—Mental disorder—Prednisone—systemic scleroderma	4.04e-05	0.000207	CcSEcCtD
Bortezomib—Nausea—Azathioprine—systemic scleroderma	4.04e-05	0.000207	CcSEcCtD
Bortezomib—PSMD1—Metabolism—CTGF—systemic scleroderma	4.03e-05	0.000465	CbGpPWpGaD
Bortezomib—Headache—Leflunomide—systemic scleroderma	4.03e-05	0.000206	CcSEcCtD
Bortezomib—Erythema—Prednisone—systemic scleroderma	4.02e-05	0.000206	CcSEcCtD
Bortezomib—Malnutrition—Prednisone—systemic scleroderma	4.02e-05	0.000206	CcSEcCtD
Bortezomib—PSMD2—Metabolism—CTGF—systemic scleroderma	4.01e-05	0.000463	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—HSPG2—systemic scleroderma	3.99e-05	0.000461	CbGpPWpGaD
Bortezomib—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	3.99e-05	0.000204	CcSEcCtD
Bortezomib—Asthenia—Lisinopril—systemic scleroderma	3.96e-05	0.000203	CcSEcCtD
Bortezomib—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	3.96e-05	0.000203	CcSEcCtD
Bortezomib—PSMB1—Gene Expression—CTGF—systemic scleroderma	3.94e-05	0.000455	CbGpPWpGaD
Bortezomib—PSMB5—Gene Expression—CTGF—systemic scleroderma	3.94e-05	0.000455	CbGpPWpGaD
Bortezomib—PSMB2—Gene Expression—CTGF—systemic scleroderma	3.94e-05	0.000455	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—HLA-DQB1—systemic scleroderma	3.91e-05	0.000452	CbGpPWpGaD
Bortezomib—Pruritus—Lisinopril—systemic scleroderma	3.91e-05	0.0002	CcSEcCtD
Bortezomib—Vomiting—Mycophenolic acid—systemic scleroderma	3.9e-05	0.0002	CcSEcCtD
Bortezomib—PSMD1—Immune System—HLA-DQB1—systemic scleroderma	3.89e-05	0.00045	CbGpPWpGaD
Bortezomib—PSMB8—Gene Expression—CTGF—systemic scleroderma	3.89e-05	0.000449	CbGpPWpGaD
Bortezomib—Haemoglobin—Methotrexate—systemic scleroderma	3.88e-05	0.000199	CcSEcCtD
Bortezomib—PSMD2—Immune System—HLA-DQB1—systemic scleroderma	3.88e-05	0.000447	CbGpPWpGaD
Bortezomib—Rash—Mycophenolic acid—systemic scleroderma	3.87e-05	0.000198	CcSEcCtD
Bortezomib—Dermatitis—Mycophenolic acid—systemic scleroderma	3.86e-05	0.000198	CcSEcCtD
Bortezomib—Hepatitis—Methotrexate—systemic scleroderma	3.86e-05	0.000198	CcSEcCtD
Bortezomib—Haemorrhage—Methotrexate—systemic scleroderma	3.86e-05	0.000198	CcSEcCtD
Bortezomib—Urticaria—Mycophenolate mofetil—systemic scleroderma	3.84e-05	0.000197	CcSEcCtD
Bortezomib—Headache—Mycophenolic acid—systemic scleroderma	3.84e-05	0.000197	CcSEcCtD
Bortezomib—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000196	CcSEcCtD
Bortezomib—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	3.83e-05	0.000196	CcSEcCtD
Bortezomib—Nausea—Leflunomide—systemic scleroderma	3.82e-05	0.000196	CcSEcCtD
Bortezomib—Urinary tract disorder—Methotrexate—systemic scleroderma	3.81e-05	0.000195	CcSEcCtD
Bortezomib—Vision blurred—Prednisone—systemic scleroderma	3.79e-05	0.000194	CcSEcCtD
Bortezomib—Urethral disorder—Methotrexate—systemic scleroderma	3.78e-05	0.000194	CcSEcCtD
Bortezomib—Diarrhoea—Lisinopril—systemic scleroderma	3.78e-05	0.000194	CcSEcCtD
Bortezomib—Ill-defined disorder—Prednisone—systemic scleroderma	3.73e-05	0.000191	CcSEcCtD
Bortezomib—Visual impairment—Methotrexate—systemic scleroderma	3.72e-05	0.000191	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL1A—systemic scleroderma	3.72e-05	0.000429	CbGpPWpGaD
Bortezomib—Anaemia—Prednisone—systemic scleroderma	3.71e-05	0.00019	CcSEcCtD
Bortezomib—PSMD1—Immune System—IL1A—systemic scleroderma	3.7e-05	0.000427	CbGpPWpGaD
Bortezomib—PSMA1—Immune System—CD40LG—systemic scleroderma	3.7e-05	0.000427	CbGpPWpGaD
Bortezomib—Agitation—Prednisone—systemic scleroderma	3.69e-05	0.000189	CcSEcCtD
Bortezomib—PSMD2—Immune System—IL1A—systemic scleroderma	3.68e-05	0.000425	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—CD40LG—systemic scleroderma	3.68e-05	0.000425	CbGpPWpGaD
Bortezomib—Angioedema—Prednisone—systemic scleroderma	3.67e-05	0.000188	CcSEcCtD
Bortezomib—PSMD2—Immune System—CD40LG—systemic scleroderma	3.66e-05	0.000423	CbGpPWpGaD
Bortezomib—Dizziness—Lisinopril—systemic scleroderma	3.65e-05	0.000187	CcSEcCtD
Bortezomib—Erythema multiforme—Methotrexate—systemic scleroderma	3.65e-05	0.000187	CcSEcCtD
Bortezomib—Nausea—Mycophenolic acid—systemic scleroderma	3.64e-05	0.000187	CcSEcCtD
Bortezomib—Malaise—Prednisone—systemic scleroderma	3.62e-05	0.000186	CcSEcCtD
Bortezomib—Vertigo—Prednisone—systemic scleroderma	3.61e-05	0.000185	CcSEcCtD
Bortezomib—Eye disorder—Methotrexate—systemic scleroderma	3.61e-05	0.000185	CcSEcCtD
Bortezomib—Syncope—Prednisone—systemic scleroderma	3.6e-05	0.000185	CcSEcCtD
Bortezomib—PSMB1—Immune System—CTLA4—systemic scleroderma	3.6e-05	0.000416	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—CTLA4—systemic scleroderma	3.6e-05	0.000416	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CTLA4—systemic scleroderma	3.6e-05	0.000416	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	3.6e-05	0.000416	CbGpPWpGaD
Bortezomib—Tinnitus—Methotrexate—systemic scleroderma	3.6e-05	0.000184	CcSEcCtD
Bortezomib—PSMB5—Signaling Pathways—RHOB—systemic scleroderma	3.59e-05	0.000414	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—RHOB—systemic scleroderma	3.59e-05	0.000414	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—RHOB—systemic scleroderma	3.59e-05	0.000414	CbGpPWpGaD
Bortezomib—Cardiac disorder—Methotrexate—systemic scleroderma	3.58e-05	0.000184	CcSEcCtD
Bortezomib—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.57e-05	0.000183	CcSEcCtD
Bortezomib—PSMB8—Immune System—CTLA4—systemic scleroderma	3.55e-05	0.00041	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—RHOB—systemic scleroderma	3.54e-05	0.000408	CbGpPWpGaD
Bortezomib—Loss of consciousness—Prednisone—systemic scleroderma	3.53e-05	0.000181	CcSEcCtD
Bortezomib—Vomiting—Lisinopril—systemic scleroderma	3.51e-05	0.00018	CcSEcCtD
Bortezomib—Angiopathy—Methotrexate—systemic scleroderma	3.5e-05	0.000179	CcSEcCtD
Bortezomib—Immune system disorder—Methotrexate—systemic scleroderma	3.49e-05	0.000179	CcSEcCtD
Bortezomib—Rash—Lisinopril—systemic scleroderma	3.48e-05	0.000179	CcSEcCtD
Bortezomib—Convulsion—Prednisone—systemic scleroderma	3.48e-05	0.000179	CcSEcCtD
Bortezomib—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—systemic scleroderma	3.48e-05	0.000402	CbGpPWpGaD
Bortezomib—Dermatitis—Lisinopril—systemic scleroderma	3.48e-05	0.000178	CcSEcCtD
Bortezomib—Mediastinal disorder—Methotrexate—systemic scleroderma	3.48e-05	0.000178	CcSEcCtD
Bortezomib—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.47e-05	0.000178	CcSEcCtD
Bortezomib—Hypertension—Prednisone—systemic scleroderma	3.47e-05	0.000178	CcSEcCtD
Bortezomib—Chills—Methotrexate—systemic scleroderma	3.46e-05	0.000177	CcSEcCtD
Bortezomib—Headache—Lisinopril—systemic scleroderma	3.46e-05	0.000177	CcSEcCtD
Bortezomib—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.42e-05	0.000176	CcSEcCtD
Bortezomib—Arthralgia—Prednisone—systemic scleroderma	3.42e-05	0.000175	CcSEcCtD
Bortezomib—Myalgia—Prednisone—systemic scleroderma	3.42e-05	0.000175	CcSEcCtD
Bortezomib—Anxiety—Prednisone—systemic scleroderma	3.41e-05	0.000175	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.4e-05	0.000174	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—HSPG2—systemic scleroderma	3.38e-05	0.000391	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—HSPG2—systemic scleroderma	3.38e-05	0.000391	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—HSPG2—systemic scleroderma	3.38e-05	0.000391	CbGpPWpGaD
Bortezomib—Discomfort—Prednisone—systemic scleroderma	3.38e-05	0.000173	CcSEcCtD
Bortezomib—Mental disorder—Methotrexate—systemic scleroderma	3.38e-05	0.000173	CcSEcCtD
Bortezomib—Malnutrition—Methotrexate—systemic scleroderma	3.36e-05	0.000172	CcSEcCtD
Bortezomib—Erythema—Methotrexate—systemic scleroderma	3.36e-05	0.000172	CcSEcCtD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.35e-05	0.000386	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—HSPG2—systemic scleroderma	3.34e-05	0.000385	CbGpPWpGaD
Bortezomib—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.31e-05	0.00017	CcSEcCtD
Bortezomib—Dysgeusia—Methotrexate—systemic scleroderma	3.29e-05	0.000169	CcSEcCtD
Bortezomib—Nausea—Lisinopril—systemic scleroderma	3.28e-05	0.000168	CcSEcCtD
Bortezomib—Oedema—Prednisone—systemic scleroderma	3.28e-05	0.000168	CcSEcCtD
Bortezomib—Anaphylactic shock—Prednisone—systemic scleroderma	3.28e-05	0.000168	CcSEcCtD
Bortezomib—PSMB1—Signaling Pathways—CSK—systemic scleroderma	3.27e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CSK—systemic scleroderma	3.27e-05	0.000377	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CSK—systemic scleroderma	3.27e-05	0.000377	CbGpPWpGaD
Bortezomib—Infection—Prednisone—systemic scleroderma	3.26e-05	0.000167	CcSEcCtD
Bortezomib—Back pain—Methotrexate—systemic scleroderma	3.25e-05	0.000167	CcSEcCtD
Bortezomib—Shock—Prednisone—systemic scleroderma	3.23e-05	0.000165	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—CSK—systemic scleroderma	3.22e-05	0.000372	CbGpPWpGaD
Bortezomib—Nervous system disorder—Prednisone—systemic scleroderma	3.22e-05	0.000165	CcSEcCtD
Bortezomib—Tachycardia—Prednisone—systemic scleroderma	3.2e-05	0.000164	CcSEcCtD
Bortezomib—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.2e-05	0.000164	CcSEcCtD
Bortezomib—Skin disorder—Prednisone—systemic scleroderma	3.19e-05	0.000163	CcSEcCtD
Bortezomib—Hyperhidrosis—Prednisone—systemic scleroderma	3.17e-05	0.000163	CcSEcCtD
Bortezomib—Vision blurred—Methotrexate—systemic scleroderma	3.17e-05	0.000162	CcSEcCtD
Bortezomib—Anorexia—Prednisone—systemic scleroderma	3.13e-05	0.00016	CcSEcCtD
Bortezomib—Ill-defined disorder—Methotrexate—systemic scleroderma	3.12e-05	0.00016	CcSEcCtD
Bortezomib—Anaemia—Methotrexate—systemic scleroderma	3.1e-05	0.000159	CcSEcCtD
Bortezomib—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.08e-05	0.000158	CcSEcCtD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	3.07e-05	0.000354	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—CTGF—systemic scleroderma	3.07e-05	0.000354	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—CTGF—systemic scleroderma	3.07e-05	0.000354	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—CTGF—systemic scleroderma	3.07e-05	0.000354	CbGpPWpGaD
Bortezomib—Rash—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000156	CcSEcCtD
Bortezomib—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.05e-05	0.000156	CcSEcCtD
Bortezomib—Headache—Mycophenolate mofetil—systemic scleroderma	3.03e-05	0.000155	CcSEcCtD
Bortezomib—Malaise—Methotrexate—systemic scleroderma	3.03e-05	0.000155	CcSEcCtD
Bortezomib—PSMB8—Metabolism—CTGF—systemic scleroderma	3.02e-05	0.000349	CbGpPWpGaD
Bortezomib—Vertigo—Methotrexate—systemic scleroderma	3.02e-05	0.000155	CcSEcCtD
Bortezomib—Leukopenia—Methotrexate—systemic scleroderma	3.01e-05	0.000154	CcSEcCtD
Bortezomib—Musculoskeletal discomfort—Prednisone—systemic scleroderma	2.99e-05	0.000153	CcSEcCtD
Bortezomib—Insomnia—Prednisone—systemic scleroderma	2.97e-05	0.000152	CcSEcCtD
Bortezomib—PSMB2—Immune System—HLA-DQB1—systemic scleroderma	2.97e-05	0.000342	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—HLA-DQB1—systemic scleroderma	2.97e-05	0.000342	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—HLA-DQB1—systemic scleroderma	2.97e-05	0.000342	CbGpPWpGaD
Bortezomib—Paraesthesia—Prednisone—systemic scleroderma	2.95e-05	0.000151	CcSEcCtD
Bortezomib—Cough—Methotrexate—systemic scleroderma	2.93e-05	0.00015	CcSEcCtD
Bortezomib—PSMB8—Immune System—HLA-DQB1—systemic scleroderma	2.92e-05	0.000338	CbGpPWpGaD
Bortezomib—Convulsion—Methotrexate—systemic scleroderma	2.91e-05	0.000149	CcSEcCtD
Bortezomib—Dyspepsia—Prednisone—systemic scleroderma	2.89e-05	0.000148	CcSEcCtD
Bortezomib—Nausea—Mycophenolate mofetil—systemic scleroderma	2.87e-05	0.000147	CcSEcCtD
Bortezomib—Chest pain—Methotrexate—systemic scleroderma	2.86e-05	0.000147	CcSEcCtD
Bortezomib—Arthralgia—Methotrexate—systemic scleroderma	2.86e-05	0.000147	CcSEcCtD
Bortezomib—Myalgia—Methotrexate—systemic scleroderma	2.86e-05	0.000147	CcSEcCtD
Bortezomib—Decreased appetite—Prednisone—systemic scleroderma	2.85e-05	0.000146	CcSEcCtD
Bortezomib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	2.84e-05	0.000146	CcSEcCtD
Bortezomib—Fatigue—Prednisone—systemic scleroderma	2.83e-05	0.000145	CcSEcCtD
Bortezomib—Discomfort—Methotrexate—systemic scleroderma	2.83e-05	0.000145	CcSEcCtD
Bortezomib—PSMB5—Immune System—IL1A—systemic scleroderma	2.82e-05	0.000325	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1A—systemic scleroderma	2.82e-05	0.000325	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1A—systemic scleroderma	2.82e-05	0.000325	CbGpPWpGaD
Bortezomib—Constipation—Prednisone—systemic scleroderma	2.8e-05	0.000144	CcSEcCtD
Bortezomib—PSMB2—Immune System—CD40LG—systemic scleroderma	2.8e-05	0.000323	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—CD40LG—systemic scleroderma	2.8e-05	0.000323	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—CD40LG—systemic scleroderma	2.8e-05	0.000323	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1A—systemic scleroderma	2.78e-05	0.000321	CbGpPWpGaD
Bortezomib—Confusional state—Methotrexate—systemic scleroderma	2.76e-05	0.000142	CcSEcCtD
Bortezomib—PSMB8—Immune System—CD40LG—systemic scleroderma	2.76e-05	0.000319	CbGpPWpGaD
Bortezomib—Anaphylactic shock—Methotrexate—systemic scleroderma	2.74e-05	0.000141	CcSEcCtD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.74e-05	0.000316	CbGpPWpGaD
Bortezomib—Infection—Methotrexate—systemic scleroderma	2.72e-05	0.00014	CcSEcCtD
Bortezomib—Feeling abnormal—Prednisone—systemic scleroderma	2.7e-05	0.000139	CcSEcCtD
Bortezomib—Nervous system disorder—Methotrexate—systemic scleroderma	2.69e-05	0.000138	CcSEcCtD
Bortezomib—Thrombocytopenia—Methotrexate—systemic scleroderma	2.68e-05	0.000138	CcSEcCtD
Bortezomib—Gastrointestinal pain—Prednisone—systemic scleroderma	2.68e-05	0.000138	CcSEcCtD
Bortezomib—Skin disorder—Methotrexate—systemic scleroderma	2.66e-05	0.000137	CcSEcCtD
Bortezomib—Hyperhidrosis—Methotrexate—systemic scleroderma	2.65e-05	0.000136	CcSEcCtD
Bortezomib—Anorexia—Methotrexate—systemic scleroderma	2.61e-05	0.000134	CcSEcCtD
Bortezomib—Urticaria—Prednisone—systemic scleroderma	2.61e-05	0.000134	CcSEcCtD
Bortezomib—Body temperature increased—Prednisone—systemic scleroderma	2.59e-05	0.000133	CcSEcCtD
Bortezomib—Abdominal pain—Prednisone—systemic scleroderma	2.59e-05	0.000133	CcSEcCtD
Bortezomib—Hypotension—Methotrexate—systemic scleroderma	2.56e-05	0.000131	CcSEcCtD
Bortezomib—CYP1A1—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.54e-05	0.000293	CbGpPWpGaD
Bortezomib—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.5e-05	0.000128	CcSEcCtD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.5e-05	0.000288	CbGpPWpGaD
Bortezomib—Insomnia—Methotrexate—systemic scleroderma	2.48e-05	0.000127	CcSEcCtD
Bortezomib—Paraesthesia—Methotrexate—systemic scleroderma	2.46e-05	0.000126	CcSEcCtD
Bortezomib—Dyspnoea—Methotrexate—systemic scleroderma	2.44e-05	0.000125	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—EDN1—systemic scleroderma	2.42e-05	0.000279	CbGpPWpGaD
Bortezomib—Hypersensitivity—Prednisone—systemic scleroderma	2.42e-05	0.000124	CcSEcCtD
Bortezomib—Dyspepsia—Methotrexate—systemic scleroderma	2.41e-05	0.000124	CcSEcCtD
Bortezomib—PSMD1—Signaling Pathways—EDN1—systemic scleroderma	2.41e-05	0.000278	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—EDN1—systemic scleroderma	2.39e-05	0.000276	CbGpPWpGaD
Bortezomib—Decreased appetite—Methotrexate—systemic scleroderma	2.38e-05	0.000122	CcSEcCtD
Bortezomib—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.37e-05	0.000121	CcSEcCtD
Bortezomib—Fatigue—Methotrexate—systemic scleroderma	2.36e-05	0.000121	CcSEcCtD
Bortezomib—Asthenia—Prednisone—systemic scleroderma	2.35e-05	0.000121	CcSEcCtD
Bortezomib—Pain—Methotrexate—systemic scleroderma	2.34e-05	0.00012	CcSEcCtD
Bortezomib—CYP2C8—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.33e-05	0.000268	CbGpPWpGaD
Bortezomib—Pruritus—Prednisone—systemic scleroderma	2.32e-05	0.000119	CcSEcCtD
Bortezomib—Feeling abnormal—Methotrexate—systemic scleroderma	2.26e-05	0.000116	CcSEcCtD
Bortezomib—Diarrhoea—Prednisone—systemic scleroderma	2.24e-05	0.000115	CcSEcCtD
Bortezomib—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.24e-05	0.000115	CcSEcCtD
Bortezomib—Urticaria—Methotrexate—systemic scleroderma	2.18e-05	0.000112	CcSEcCtD
Bortezomib—Dizziness—Prednisone—systemic scleroderma	2.17e-05	0.000111	CcSEcCtD
Bortezomib—Abdominal pain—Methotrexate—systemic scleroderma	2.17e-05	0.000111	CcSEcCtD
Bortezomib—Body temperature increased—Methotrexate—systemic scleroderma	2.17e-05	0.000111	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—HSPG2—systemic scleroderma	2.13e-05	0.000246	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—HSPG2—systemic scleroderma	2.12e-05	0.000244	CbGpPWpGaD
Bortezomib—PSMA1—Disease—NOS3—systemic scleroderma	2.1e-05	0.000243	CbGpPWpGaD
Bortezomib—PSMD1—Disease—NOS3—systemic scleroderma	2.09e-05	0.000242	CbGpPWpGaD
Bortezomib—Vomiting—Prednisone—systemic scleroderma	2.09e-05	0.000107	CcSEcCtD
Bortezomib—PSMD2—Disease—NOS3—systemic scleroderma	2.08e-05	0.00024	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	2.08e-05	0.00024	CbGpPWpGaD
Bortezomib—Rash—Prednisone—systemic scleroderma	2.07e-05	0.000106	CcSEcCtD
Bortezomib—Dermatitis—Prednisone—systemic scleroderma	2.07e-05	0.000106	CcSEcCtD
Bortezomib—Headache—Prednisone—systemic scleroderma	2.05e-05	0.000105	CcSEcCtD
Bortezomib—Hypersensitivity—Methotrexate—systemic scleroderma	2.02e-05	0.000104	CcSEcCtD
Bortezomib—Asthenia—Methotrexate—systemic scleroderma	1.97e-05	0.000101	CcSEcCtD
Bortezomib—Nausea—Prednisone—systemic scleroderma	1.95e-05	9.99e-05	CcSEcCtD
Bortezomib—Pruritus—Methotrexate—systemic scleroderma	1.94e-05	9.94e-05	CcSEcCtD
Bortezomib—PSMA1—Immune System—IL1B—systemic scleroderma	1.94e-05	0.000224	CbGpPWpGaD
Bortezomib—PSMD1—Immune System—IL1B—systemic scleroderma	1.93e-05	0.000223	CbGpPWpGaD
Bortezomib—PSMD2—Immune System—IL1B—systemic scleroderma	1.92e-05	0.000222	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.89e-05	0.000218	CbGpPWpGaD
Bortezomib—Diarrhoea—Methotrexate—systemic scleroderma	1.88e-05	9.62e-05	CcSEcCtD
Bortezomib—PSMB2—Signaling Pathways—EDN1—systemic scleroderma	1.83e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—EDN1—systemic scleroderma	1.83e-05	0.000211	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—EDN1—systemic scleroderma	1.83e-05	0.000211	CbGpPWpGaD
Bortezomib—Dizziness—Methotrexate—systemic scleroderma	1.81e-05	9.29e-05	CcSEcCtD
Bortezomib—PSMB8—Signaling Pathways—EDN1—systemic scleroderma	1.81e-05	0.000209	CbGpPWpGaD
Bortezomib—PSMA1—Metabolism—NOS3—systemic scleroderma	1.76e-05	0.000203	CbGpPWpGaD
Bortezomib—PSMD1—Metabolism—NOS3—systemic scleroderma	1.75e-05	0.000202	CbGpPWpGaD
Bortezomib—PSMD2—Metabolism—NOS3—systemic scleroderma	1.74e-05	0.000201	CbGpPWpGaD
Bortezomib—Vomiting—Methotrexate—systemic scleroderma	1.74e-05	8.94e-05	CcSEcCtD
Bortezomib—Rash—Methotrexate—systemic scleroderma	1.73e-05	8.86e-05	CcSEcCtD
Bortezomib—Dermatitis—Methotrexate—systemic scleroderma	1.73e-05	8.85e-05	CcSEcCtD
Bortezomib—Headache—Methotrexate—systemic scleroderma	1.72e-05	8.8e-05	CcSEcCtD
Bortezomib—PSMA1—Signaling Pathways—CCL2—systemic scleroderma	1.65e-05	0.000191	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—CCL2—systemic scleroderma	1.64e-05	0.00019	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—CCL2—systemic scleroderma	1.64e-05	0.000189	CbGpPWpGaD
Bortezomib—Nausea—Methotrexate—systemic scleroderma	1.63e-05	8.35e-05	CcSEcCtD
Bortezomib—CYP1A2—Metabolism of lipids and lipoproteins—CTGF—systemic scleroderma	1.62e-05	0.000187	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—CTGF—systemic scleroderma	1.6e-05	0.000185	CbGpPWpGaD
Bortezomib—PSMB5—Disease—NOS3—systemic scleroderma	1.59e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB1—Disease—NOS3—systemic scleroderma	1.59e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB2—Disease—NOS3—systemic scleroderma	1.59e-05	0.000184	CbGpPWpGaD
Bortezomib—PSMB8—Disease—NOS3—systemic scleroderma	1.57e-05	0.000181	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—HSPG2—systemic scleroderma	1.49e-05	0.000172	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—NOS3—systemic scleroderma	1.47e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB5—Immune System—IL1B—systemic scleroderma	1.47e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB1—Immune System—IL1B—systemic scleroderma	1.47e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMB2—Immune System—IL1B—systemic scleroderma	1.47e-05	0.00017	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—NOS3—systemic scleroderma	1.47e-05	0.000169	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—NOS3—systemic scleroderma	1.46e-05	0.000168	CbGpPWpGaD
Bortezomib—PSMB8—Immune System—IL1B—systemic scleroderma	1.45e-05	0.000167	CbGpPWpGaD
Bortezomib—PSMA1—Disease—TGFB1—systemic scleroderma	1.39e-05	0.000161	CbGpPWpGaD
Bortezomib—PSMD1—Disease—TGFB1—systemic scleroderma	1.38e-05	0.00016	CbGpPWpGaD
Bortezomib—PSMD2—Disease—TGFB1—systemic scleroderma	1.38e-05	0.000159	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—HSPG2—systemic scleroderma	1.37e-05	0.000158	CbGpPWpGaD
Bortezomib—PSMB5—Metabolism—NOS3—systemic scleroderma	1.33e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB2—Metabolism—NOS3—systemic scleroderma	1.33e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB1—Metabolism—NOS3—systemic scleroderma	1.33e-05	0.000154	CbGpPWpGaD
Bortezomib—PSMB8—Metabolism—NOS3—systemic scleroderma	1.32e-05	0.000152	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—CCL2—systemic scleroderma	1.25e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—CCL2—systemic scleroderma	1.25e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—CCL2—systemic scleroderma	1.25e-05	0.000145	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—CCL2—systemic scleroderma	1.23e-05	0.000143	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—HSPG2—systemic scleroderma	1.22e-05	0.000141	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—MMP9—systemic scleroderma	1.18e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—MMP9—systemic scleroderma	1.18e-05	0.000136	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—MMP9—systemic scleroderma	1.17e-05	0.000135	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—CTGF—systemic scleroderma	1.13e-05	0.00013	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—HSPG2—systemic scleroderma	1.12e-05	0.00013	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—NOS3—systemic scleroderma	1.12e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—NOS3—systemic scleroderma	1.12e-05	0.000129	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—NOS3—systemic scleroderma	1.12e-05	0.000129	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—HSPG2—systemic scleroderma	1.11e-05	0.000128	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—NOS3—systemic scleroderma	1.1e-05	0.000127	CbGpPWpGaD
Bortezomib—PSMB1—Disease—TGFB1—systemic scleroderma	1.05e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB5—Disease—TGFB1—systemic scleroderma	1.05e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB2—Disease—TGFB1—systemic scleroderma	1.05e-05	0.000122	CbGpPWpGaD
Bortezomib—PSMB8—Disease—TGFB1—systemic scleroderma	1.04e-05	0.00012	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—CTGF—systemic scleroderma	1.04e-05	0.00012	CbGpPWpGaD
Bortezomib—PSMA1—Signaling Pathways—TGFB1—systemic scleroderma	9.74e-06	0.000112	CbGpPWpGaD
Bortezomib—PSMD1—Signaling Pathways—TGFB1—systemic scleroderma	9.69e-06	0.000112	CbGpPWpGaD
Bortezomib—PSMD2—Signaling Pathways—TGFB1—systemic scleroderma	9.65e-06	0.000111	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—HSPG2—systemic scleroderma	9.5e-06	0.00011	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—CTGF—systemic scleroderma	9.24e-06	0.000107	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—MMP9—systemic scleroderma	8.95e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—MMP9—systemic scleroderma	8.95e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—MMP9—systemic scleroderma	8.95e-06	0.000103	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—MMP9—systemic scleroderma	8.83e-06	0.000102	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—CTGF—systemic scleroderma	8.5e-06	9.81e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—CTGF—systemic scleroderma	8.43e-06	9.73e-05	CbGpPWpGaD
Bortezomib—PSMB2—Signaling Pathways—TGFB1—systemic scleroderma	7.38e-06	8.52e-05	CbGpPWpGaD
Bortezomib—PSMB5—Signaling Pathways—TGFB1—systemic scleroderma	7.38e-06	8.52e-05	CbGpPWpGaD
Bortezomib—PSMB1—Signaling Pathways—TGFB1—systemic scleroderma	7.38e-06	8.52e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—HSPG2—systemic scleroderma	7.33e-06	8.47e-05	CbGpPWpGaD
Bortezomib—PSMB8—Signaling Pathways—TGFB1—systemic scleroderma	7.28e-06	8.4e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—CTGF—systemic scleroderma	7.2e-06	8.31e-05	CbGpPWpGaD
Bortezomib—PTGS1—Metabolism—NOS3—systemic scleroderma	6.98e-06	8.06e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—CTGF—systemic scleroderma	5.56e-06	6.42e-05	CbGpPWpGaD
Bortezomib—CYP1A1—Metabolism—NOS3—systemic scleroderma	4.92e-06	5.68e-05	CbGpPWpGaD
Bortezomib—CYP2C8—Metabolism—NOS3—systemic scleroderma	4.51e-06	5.2e-05	CbGpPWpGaD
Bortezomib—CYP2C19—Metabolism—NOS3—systemic scleroderma	4.02e-06	4.64e-05	CbGpPWpGaD
Bortezomib—CYP2D6—Metabolism—NOS3—systemic scleroderma	3.7e-06	4.27e-05	CbGpPWpGaD
Bortezomib—CYP2C9—Metabolism—NOS3—systemic scleroderma	3.67e-06	4.24e-05	CbGpPWpGaD
Bortezomib—CYP1A2—Metabolism—NOS3—systemic scleroderma	3.13e-06	3.62e-05	CbGpPWpGaD
Bortezomib—CYP3A4—Metabolism—NOS3—systemic scleroderma	2.42e-06	2.79e-05	CbGpPWpGaD
